Rates of pneumonia among children and adults with chronic medical conditions in Germany

BMC Infectious Diseases

Derek Weycker³  Elana S. Gruen³  Rogier Klok⁵  Christian Jacob⁶  Sebastian Braun⁶  David R. Strutton²  Raymond A. Farkouh²  Kimberly M. Shea⁴  Stephen I. Pelton¹ 

[1] Maxwell Finland Laboratory for Infectious Diseases, 670 Albany Street, 6th Floor, Boston 02118, MA, USA;Pfizer Inc., Collegeville, PA, USA;Policy Analysis Inc. (PAI), Brookline, MA, USA;Boston University School of Public Health, Boston, MA, USA;Pfizer bv, Capelle a/d IJssel, Netherlands;Xcenda GmbH, Hannover, Germany

关键词: Germany;    Comorbidity;    Pneumonia;    Pneumococcal infections;    Streptococcus pneumoniae;   

Others  :  1232684
DOI  :  10.1186/s12879-015-1162-y

 received in 2015-04-30, accepted in 2015-09-30,  发布年份 2015

【 摘 要 】

Background

The objective of this study is to evaluate rates of all-cause pneumonia among “at-risk” and “high-risk” children and adults in Germany—in comparison with age-stratified healthy counterparts—during the period following the 2006 recommendation for universal immunization of infants with pneumococcal conjugate vaccine.

Methods

Retrospective cohort design and healthcare claims information for 3.4 M persons in Germany (2009–2012) were employed. Study population was stratified by age and risk profile (healthy, “at-risk” [with chronic medical conditions], and “high-risk” [immunocompromised]). At-risk and high-risk conditions, as well as episodes of all-cause pneumonia, were identified via diagnosis, procedure, and drug codes.

Results and discussion

Rates of all-cause pneumonia were 1.7 (95 % CI 1.7-1.8) to 2.5 (2.4-2.5) times higher among children and adults with at-risk conditions versus healthy counterparts, and 1.8 (1.8-1.9) to 4.1 (4.0-4.2) times higher among children and adults with high-risk conditions. Rates of all-cause pneumonia among at-risk persons increased in a graded and monotonic fashion with increasing numbers of conditions (i.e., risk stacking).

Conclusions

An increased risk for all-cause pneumonia in German children and adults with a spectrum of medical conditions persists in the era of widespread pneumococcal vaccination, and pneumonia risk in persons with ≥2 at-risk conditions is comparable or higher than those with high-risk conditions.

【 授权许可】

   
2015 Pelton et al.

【 图 表 】

Fig. 1.

Fig. 2.

【 参考文献 】

• [1]Schnoor M, Hedicke J, Dalhoff K, Raspe H, Schäfer T. Approaches to estimate the population-based incidence of community acquired pneumonia. J Infect. 2007; 55(3):233-9.
• [2]AQUA Institut GmbH, Bundesauswertung 2013, PNEU–Ambulant erworbene Pneumonie Qualitaetsingikatoren. 2014
• [3]Ewig S, Birkner N, Strauss R, Schaefer E, Pauletzki J, Bischoff H et al.. New perspectives on community-acquired pneumonia in 388 406 patients. Results from a nationwide mandatory performance measurement programme in healthcare quality. Thorax. 2009; 64:1062-9.
• [4]Welte T, Torres A, Nathwani D. Clinical and economic burden of community-acquired pneumonia among adults in Europe. Thorax. 2012; 67(1):71-9.
• [5]Rozenbaum MH, Pechlivanoglou P, van der Werf TS, Lo-Ten-Foe JR, Postma MJ, Hak E. The role of streptococcus pneumonia in community-acquired pneumonia among adults in Europe: a meta-analysis. Eur J Clin Microbiol Infect Dis. 2013; 32(3):305-16.
• [6]Grijalva CG, Nuorti JP, Arbogast PG, Martin SW, Edwards KM, Griffin MR. Decline in pneumonia admissions after routine childhood immunization with pneumococcal conjugate vaccine in the USA: a time-series analysis. Lancet. 2007; 369:1179-86.
• [7]Hicks LA, Harrison LH, Flannery B, Hadler JL, Schaffner W, Craig AS et al.. Incidence of pneumococcal disease due to non-pneumococcal conjugate vaccine (PCV7) serotypes in the United States during the era of widespread PCV7 vaccination, 1998–2004. J Infec Dis. 2007; 196:1346-54.
• [8]Lexau CA, Lynfield R, Danila R, Pilishvili T, Facklam R, Farley MM et al.. Changing epidemiology of invasive pneumococcal disease among older adults in the era of pediatric pneumococcal conjugate vaccine. JAMA. 2005; 294:2043-51.
• [9]Pilishvili T, Lexau C, Farley MM, Hadler J, Harrison LH, Bennett NM et al.. Sustained reductions in invasive pneumococcal disease in the era of conjugate vaccine. J Infect Dis. 2010; 201:32-41.
• [10]Moore M, Link-Gelles R, Farley MM, Schaffner W, Thomas A, Reingold A et al.. Impact of 13-valent pneumococcal conjugate vaccine on invasive pneumococcal disease, US 2010–11, oral presentation at ID Week. 2012.
• [11]Griffin MR, Zhu Y, Moore MR, Whitney CG, Grijalva CG. US hospitalizations for pneumonia after a decade of pneumococcal vaccination. NEJM. 2013; 369(2):155-63.
• [12]Miller E, Andrews NJ, Waight PA, Slack MP, George RC. Herd immunity and serotype replacement 4 years after seven-valent pneumococcal conjugate vaccination in England and Wales: an observational cohort study. Lancet Infect Dis. 2011; 11(10):760-8.
• [13]Shea KM, Edelsberg J, Weycker D, Farkouh RA, Strutton DR, Pelton SI. Rates of pneumococcal disease in adults with chronic medical conditions. Open Forum Infect Dis. 2014;1(1). doi:10.1007/s00431-014-2409-0
• [14]Wotton CJ, Goldacre MJ. Risk of invasive pneumococcal disease in people admitted to hospital with selected immune-mediated diseases: record linkage cohort analyses. J Epidemiol Community Health. 2012; 66(12):1177-81.
• [15]Vinogradova Y, Hippisley-Cox J, Coupland C. Identification of new risk factors for pneumonia: population-based case–control study. Br J Gen Pract. 2009; 59(567):e329-38.
• [16]Bhat N, Wright JG, Broder KR, Murray EL, Greenberg ME, Glover MJ et al.. Influenza-associated deaths among children in the United States, 2003–2004. N Engl J Med. 2005; 353(24):2559-67.
• [17]van der Linden M, Imöhl M, Busse A, Rose M, Adam D. Bacterial sprectrum of spontaneously ruptured otitis media in the era of pneumococcal conjugate vaccination in Germany. Eur J Pediatr. 2014.
• [18]van der Linden M, Perniciaro S, Imöhl M. Effects of 5 years of immunization with higher valent pneumococcal conjugate vaccines in German children. Poster presented at European Society for Paediatric Infectious Diseases, Dublin; 2014.
• [19]van der Linden M, Weiss S, Falkenhorst G, Siedler A, Imöhl M, von Kries R. Four years of universal pneumococcal conjugate infant vaccination in Germany: Impact on incidence of invasive pneumococcal disease and serotype distribution in children. Vaccine. 2012; 30:5880-5.
• [20]Laurenz M, Sprenger R, von Eiff C, Busse A. Reduced incidence of otitis media among children in Germany after introduction of higher-valent pneumococcal conjugate vaccines. Poster presented at European Society for Paediatric Infectious Diseases, Dublin; 2014.
• [21]Laurenz M, Sprenger R, von Eiff C, Busse A. Reduced incidence of pneumonia among children in Germany after introduction of higher-valent pneumococcal conjugate vaccines. Poster presented at European Society for Paediatric Infectious Diseases, Dublin; 2014.
• [22]Pelton SI, Weycker D, Farkouh RA, Strutton DR, Shea KM, Edelsberg J. Risk of pneumococcal disease in children with chronic medical conditions in the era of pneumococcal conjugate vaccine. Clin Infect Dis. 2014; 59(5):615-23.
• [23]Muhammad RD, Oza-Frank R, Zell E, Link-Gelles R, Narayan KM, Schaffner W et al.. Epidemiology of invasive pneumococcal disease among high-risk adults since the introduction of pneumococcal conjugate vaccine for children. Clin Infect Dis. 2013; 56(5):e59-67.
• [24]van Hoek AJ, Andrews N, Waight P, Stowe J, Gates P, George R et al.. The effect of underlying clinical conditions on the risk of developing invasive pneumococcal disease in England. J Infect. 2012; 65(1):17-24.
• [25]Jain S, Williams DJ, Arnold SR, Ampofo K, Bramley AM, Reed C et al.. Community-acquired pneumonia requiring hospitalization among U.S. children. NEJM. 2015; 372(9):45.
• [26]Griffin MR, Mitchel E, Moore MR, Whitney CG, Grijalva CG. Declines in pneumonia hospitalization of children aged <2 years associated with the use of pneumococcal conjugate vaccine – Tennessee, 1998–2012. MMWR. 2014; 63(44):995-8.
• [27]Pelton SI, Shea KM, Weycker D, Farkouh RA, Strutton DR, Edelsberg J. Rethinking risk for pneumococcal disease in adults: The role of risk stacking. Open Forum Infect Dis. 2015. [Epub ahead of print].
• [28]Yildirim I, Shea KM, Little BA, Silverio AL, Pelton SI. Vaccination, underlying comorbidities, and risk ofinvasive pneumococcal disease. Pediatrics. 2015; 135(3):495-503. doi:10.1542/peds.2014-2426. Epub 2015 Feb 2.